The meningitis shot is a vaccine that protects against meningococcal disease, a bacterial infection that can cause life-threatening inflammation of the membranes surrounding the brain and spinal cord. There are several versions of the vaccine, each targeting different strains of the bacteria, but the most common one given to preteens in the U.S. covers four major bacterial strains (A, C, W, and Y) and is recommended at ages 11 to 12 with a booster at 16.
Types of Meningitis Vaccines
Meningococcal bacteria come in several serogroups, and no single vaccine has historically covered all of them. That’s why there are different shots targeting different strains:
- MenACWY vaccines protect against four serogroups: A, C, W, and Y. These are the ones routinely given to all preteens and teens. Brand names include Menveo and MenQuadfi.
- MenB vaccines protect against serogroup B, which causes a significant share of cases in adolescents and young adults. Brand names include Bexsero and Trumenba. These are not part of the routine schedule for all teens but can be given based on a conversation with a healthcare provider, typically between ages 16 and 18.
- MenABCWY vaccines are newer pentavalent (five-in-one) vaccines that combine protection against all five serogroups: A, B, C, W, and Y. Penmenvy, one of these pentavalent vaccines, was licensed for people ages 10 to 25 and can be used when both MenACWY and MenB protection are needed at the same visit.
The pentavalent option simplifies things considerably. Instead of needing separate shots for the four-strain and B-strain vaccines, eligible people can now get coverage against all five serogroups in a single product.
Who Needs It and When
The CDC recommends all preteens get a MenACWY vaccine at 11 or 12, followed by a booster at age 16. That booster matters because protection fades over time, and 16 through 21 is the age range with the highest risk of meningococcal disease. Teens who receive their first dose at or after 16 don’t need a separate booster.
Many colleges require proof of MenACWY vaccination within the five years before enrollment. Even without a school requirement, the CDC recommends catching up on the booster if the first dose was given before age 16.
The MenB vaccine follows different rules. It’s not universally recommended for all teens. Instead, it falls under what’s called shared clinical decision-making, meaning you and your provider decide together whether it makes sense, typically between ages 16 and 23.
Higher-Risk Groups
Certain medical conditions make meningococcal infection more likely and more dangerous. People with complement component deficiencies (parts of the immune system that help fight bacteria), those without a functioning spleen (including people with sickle cell disease), and people living with HIV are all recommended to receive both MenACWY and MenB vaccines, often on an accelerated or expanded schedule. For these individuals, the pentavalent vaccine can be used starting at age 10 when both types of coverage are indicated at the same visit.
Travel is another factor. Saudi Arabia requires proof of meningococcal vaccination for Hajj and Umrah pilgrims. Parts of sub-Saharan Africa, known as the “meningitis belt,” also carry higher risk, and vaccination is recommended before travel to these regions.
How the Vaccine Works
Modern meningitis vaccines use a technology called conjugation. The outer coating (polysaccharide) of the meningococcal bacteria is attached to a carrier protein. This combination trains the immune system more effectively than older polysaccharide-only vaccines, which couldn’t generate lasting memory in immune cells.
The conjugate approach triggers a stronger, more durable response. Your immune system produces higher-quality antibodies, retains memory of the bacteria, and responds faster if you’re exposed in the future. This is also why conjugate vaccines work in young children, while older polysaccharide-only vaccines did not.
MenB vaccines work differently. Instead of targeting the outer sugar coating, they use proteins found on the surface of serogroup B bacteria to trigger immunity, since the B serogroup’s coating is poorly recognized by the immune system.
How Effective It Is
A study published in JAMA Network Open estimated that without the routine MenACWY vaccination program, cases of invasive meningococcal disease among U.S. adolescents and young adults would have been at least 59% higher than what was actually reported during the vaccine era. That’s a substantial reduction in a disease that, while uncommon, kills about 10 to 15% of those it infects and leaves lasting complications in many survivors.
How Long Protection Lasts
Antibody levels do decline after vaccination, which is why the booster at 16 exists. Research on the MenACWY conjugate vaccine shows that five years after a priming dose, antibody levels are still higher than pre-vaccination levels, indicating meaningful long-term persistence. After an initial drop in the first year or two, antibody levels tend to stabilize and hold relatively steady between 6 and 10 years post-vaccination.
The booster at 16 reactivates immune memory and raises protection during the late teen and early college years, when exposure risk from close-quarters living and social behavior is highest.
Side Effects
The meningitis shot causes side effects in most people, but they’re overwhelmingly mild and short-lived. Data from clinical trials of the MenB vaccine (Bexsero) gives a detailed picture of what to expect:
- Injection-site pain is the most common reaction, reported by about 84% of recipients. Redness, swelling, and hardness at the injection site each occur in roughly 25 to 30% of people.
- Fatigue affects about 51% of recipients, and headache about 42%.
- Muscle aches and trouble sleeping each occur in about 40% of people.
- Fever is less common than many people expect, with a pooled incidence of only about 8%.
- Nausea, chills, and diarrhea each affect fewer than 1 in 5 recipients.
These numbers look high, but context matters. “Pain at the injection site” includes mild soreness, and “fatigue” includes feeling slightly more tired than usual for a day. Most side effects resolve within 24 to 48 hours. Serious allergic reactions are rare and represent the primary contraindication for future doses. Anyone who has had anaphylaxis after a previous meningococcal vaccine dose or to any component in the vaccine should not receive additional doses of that type.
The Pentavalent Vaccine Option
The approval of pentavalent meningococcal vaccines represents a practical improvement for teens and young adults. Penmenvy, licensed for ages 10 to 25, contains the same active components as the existing Menveo (MenACWY) and Bexsero (MenB) vaccines combined into one product. For a 16-year-old who needs both the MenACWY booster and decides to get MenB coverage, this means fewer total shots.
The CDC’s Advisory Committee on Immunization Practices has recommended that the pentavalent vaccine can be used for healthy people ages 16 to 23 when both vaccine types would be given at the same visit, and for anyone 10 and older who is at increased risk due to conditions like complement deficiencies, complement inhibitor use, or a missing or nonfunctioning spleen.